Esperion Therapeutics Company Profile (NASDAQ:ESPR)

About Esperion Therapeutics

Esperion Therapeutics logoEsperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company's segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company's lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ESPR
  • CUSIP:
Key Metrics:
  • Previous Close: $24.37
  • 50 Day Moving Average: $15.91
  • 200 Day Moving Average: $12.82
  • 52-Week Range: $9.40 - $26.10
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.42
  • P/E Growth: 0.77
  • Market Cap: $549.62M
  • Outstanding Shares: 22,553,000
  • Beta: 2.1
Profitability:
  • Return on Equity: -21.76%
  • Return on Assets: -21.07%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 26.16%
  • Quick Ratio: 26.16%
Additional Links:
Companies Related to Esperion Therapeutics:

Analyst Ratings

Consensus Ratings for Esperion Therapeutics (NASDAQ:ESPR) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $26.54 (8.91% upside)

Analysts' Ratings History for Esperion Therapeutics (NASDAQ:ESPR)
Show:
DateFirmActionRatingPrice TargetDetails
2/23/2017Royal Bank Of CanadaReiterated RatingSector Perform -> Sector Perform$20.00 -> $30.00View Rating Details
2/23/2017RBC Capital MarketsReiterated RatingSector Perform$20.00 -> $30.00View Rating Details
2/4/2017Needham & Company LLCSet Price TargetBuy$25.00View Rating Details
12/20/2016Credit Suisse GroupReiterated RatingSell$12.00View Rating Details
11/14/2016Citigroup Inc.DowngradeBuy -> NeutralView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyView Rating Details
10/15/2016Stifel NicolausReiterated RatingBuy$64.00 -> $30.00View Rating Details
10/15/2016Chardan CapitalReiterated RatingNeutral$12.50View Rating Details
8/31/2016Barclays PLCSet Price TargetHold$13.00View Rating Details
8/5/2016J P Morgan Chase & CoSet Price TargetHold$15.00View Rating Details
7/5/2016WallachBeth CapitalDowngradeBuy -> Hold$35.00View Rating Details
6/29/2016Lake Street CapitalLower Price TargetBuy$80.00 -> $27.00View Rating Details
11/6/2015Bank of America CorpReiterated RatingBuy$65.00View Rating Details
8/17/2015FIXReiterated RatingaddView Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Esperion Therapeutics (NASDAQ:ESPR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017        
2/22/201712/31/2016($1.24)($1.29)ViewN/AView Earnings Details
11/3/2016Q3($0.82)($0.77)ViewN/AView Earnings Details
8/4/2016Q2($0.78)($0.62)ViewN/AView Earnings Details
5/4/2016Q116($0.74)($0.65)ViewN/AView Earnings Details
2/25/2016Q4($0.61)($0.58)ViewN/AView Earnings Details
11/5/2015Q3($0.60)($0.57)ViewN/AView Earnings Details
8/6/2015Q215($0.58)($0.55)ViewN/AView Earnings Details
5/7/2015Q115($0.48)($0.56)ViewN/AView Earnings Details
3/5/2015($0.54)($0.49)ViewN/AView Earnings Details
8/12/2014Q214$0.60$0.60ViewN/AView Earnings Details
5/12/2014($0.62)($0.51)ViewN/AView Earnings Details
3/5/2014($0.50)($0.63)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Esperion Therapeutics (NASDAQ:ESPR)
Current Year EPS Consensus Estimate: $-3.33 EPS
Next Year EPS Consensus Estimate: $-4.50 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.82)($0.82)($0.82)
Q2 20161($0.78)($0.78)($0.78)
Q3 20161($1.02)($1.02)($1.02)
Q4 20161($1.28)($1.28)($1.28)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Esperion Therapeutics (NASDAQ:ESPR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Esperion Therapeutics (NASDAQ:ESPR)
Insider Ownership Percentage: 35.40%
Institutional Ownership Percentage: 64.65%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/1/2016Narendra D LalwaniCOOBuy5,000$9.93$49,650.00View SEC Filing  
7/6/2016Mark E McgovernDirectorBuy5,000$10.00$50,000.00View SEC Filing  
5/4/2016Timothy M MaylebenCEOBuy7,000$14.85$103,950.00View SEC Filing  
3/1/2016Gilbert S OmennDirectorBuy5,000$15.28$76,400.00View SEC Filing  
1/27/2016Timothy M MaylebenCEOBuy3,600$15.88$57,168.00View SEC Filing  
1/15/2016Timothy M MaylebenCEOBuy7,200$14.08$101,376.00View SEC Filing  
4/24/2015Dov A Md GoldsteinDirectorSell217,469$108.22$23,534,495.18View SEC Filing  
11/18/2014Patrick G EnrightDirectorSell487,130$32.78$15,968,121.40View SEC Filing  
10/21/2014Parters Vii L P DomainMajor ShareholderBuy500,000$20.00$10,000,000.00View SEC Filing  
10/7/2014Longitude Capital Partners, LlMajor ShareholderSell11,927$30.04$358,287.08View SEC Filing  
7/1/2013Brian H DoveyMajor ShareholderBuy285,714$14.00$3,999,996.00View SEC Filing  
7/1/2013Daniel JanneyDirectorBuy235,714$14.00$3,299,996.00View SEC Filing  
7/1/2013Roger S NewtonChairmanBuy42,346$14.00$592,844.00View SEC Filing  
7/1/2013Timothy M MaylebenCEOBuy5,000$14.00$70,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Esperion Therapeutics (NASDAQ:ESPR)
DateHeadline
News IconArsenal & Manchester United linked with 50 million rated Portuguese striker (NASDAQ:ESPR)
latribunadecanarias.com - February 23 at 10:05 PM
News IconBrit awards 2017: George Michael tributes, Little Mix, Skepta and more (NASDAQ:ESPR)
fairydetox.org - February 23 at 5:02 PM
News IconCards Against Humanity is getting a Mass Effect expansion (NASDAQ:ESPR)
ekosvoice.com - February 23 at 5:02 PM
marketexclusive.com logoAnalyst Activity – Royal Bank Of Canada Reiterates Sector Perform on Esperion Therapeutics (NASDAQ:ESPR) (NASDAQ:ESPR)
marketexclusive.com - February 23 at 5:02 PM
thestreet.com logoFirst Week of April 21st Options Trading For Esperion Therapeutics - TheStreet.com (NASDAQ:ESPR)
www.thestreet.com - February 22 at 10:19 PM
News IconOverbuying Stock under Radar: Esperion Therapeutics Inc (NASDAQ:ESPR) (NASDAQ:ESPR)
brassale.net - February 22 at 8:33 AM
4-traders.com logoEsperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Results of Operations and Financial Condition (NASDAQ:ESPR)
www.4-traders.com - February 22 at 8:33 AM
us.rd.yahoo.com logoEsperion Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:ESPR)
us.rd.yahoo.com - February 22 at 8:33 AM
us.rd.yahoo.com logo7:37 am Esperion Therapeutics misses by $0.05; provides update, gives cash outlook (NASDAQ:ESPR)
us.rd.yahoo.com - February 22 at 8:33 AM
biz.yahoo.com logoESPERION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a (NASDAQ:ESPR)
us.rd.yahoo.com - February 22 at 8:33 AM
sg.finance.yahoo.com logoEsperion Therapeutics reports 4Q loss (NASDAQ:ESPR)
sg.finance.yahoo.com - February 22 at 8:33 AM
News IconThe Way Wall Street Experts See Esperion Therapeutics, Inc. (ESPR ... - Post Analyst (NASDAQ:ESPR)
postanalyst.com - February 20 at 4:40 PM
News IconA Keen Look At The Chart For Esperion Therapeutics, Inc. (ESPR) - NY Stock News (NASDAQ:ESPR)
nystocknews.com - February 18 at 10:59 AM
4-traders.com logoEsperion Therapeutics : to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference (NASDAQ:ESPR)
www.4-traders.com - February 16 at 4:49 PM
News IconEsperion To Participate In Fireside Chat At Conference (NASDAQ:ESPR)
www.biospace.com - February 16 at 4:49 PM
finance.yahoo.com logoEsperion to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference (NASDAQ:ESPR)
finance.yahoo.com - February 16 at 4:49 PM
finance.yahoo.com logoEsperion Positioned to Capitalize on Phase III Trials (NASDAQ:ESPR)
finance.yahoo.com - February 13 at 5:52 PM
nasdaq.com logo4 Stocks to Watch, Led by Biotech (NASDAQ:ESPR)
www.nasdaq.com - February 9 at 10:39 PM
marketwatch.com logoOpinion: Harry Boxer's stocks to watch: biotechnology and technology - MarketWatch (NASDAQ:ESPR)
www.marketwatch.com - February 9 at 5:37 PM
marketwatch.com logoHarry Boxer’s stocks to watch: biotechnology and technology (NASDAQ:ESPR)
www.marketwatch.com - February 9 at 5:37 PM
News IconTechnical Levels in Review for Esperion Therapeutics Inc. (ESPR) - Benton Bulletin (NASDAQ:ESPR)
bentonbulletin.com - February 8 at 10:33 PM
News IconEsperion Therapeutics, Inc. (NASDAQ:ESPR) Insider Ownership stands at 31.62 - The Newburgh Press (NASDAQ:ESPR)
newburghpress.com - February 8 at 4:17 AM
News IconFor Trump foes, Democratic gains may remain elusive in 2018 (NASDAQ:ESPR)
mundoaguaysaneamiento.net - February 7 at 6:16 PM
benzinga.com logoEsperion Surge May Be Fueled By Repatha Short Squeeze (NASDAQ:ESPR)
www.benzinga.com - February 7 at 6:16 PM
News IconPast 3 Quarter Report of Himax Technologies, Inc. (NASDAQ:HIMX) (NASDAQ:ESPR)
mundoaguaysaneamiento.net - February 6 at 10:09 PM
insidermonkey.com logoWhat’s Next For Esperion Therapeutics Inc (ESPR)? (NASDAQ:ESPR)
www.insidermonkey.com - February 6 at 5:07 PM
rttnews.com logoESPR, MDCO Riding High, New Uses For MRK's Old Drug, DBVT In Full Smile(e) (NASDAQ:ESPR)
www.rttnews.com - February 6 at 9:58 AM
marketexclusive.com logoWhat’s Next For Esperion Therapeutics Inc (NASDAQ:ESPR)? (NASDAQ:ESPR)
marketexclusive.com - February 6 at 9:58 AM
finance.yahoo.com logoMergers & Acquisitions Could be a Key Catalyst Sending These Biotech Stocks to New Highs in 2017 (NASDAQ:ESPR)
finance.yahoo.com - February 6 at 9:58 AM
fool.com logoWhy Esperion Therapeutics, Inc. Is Soaring Today (NASDAQ:ESPR)
www.fool.com - February 3 at 3:45 PM
News IconIncrease in Volatility Draws Attention to Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Wall Street Beacon (NASDAQ:ESPR)
wsbeacon.com - February 1 at 5:38 PM
News IconEsperion Therapeutics, Inc. (NASDAQ:ESPR) Stock ABR At 2.67 ... - Stock Observer (NASDAQ:ESPR)
www.thestockobserver.com - January 29 at 5:06 PM
News IconInvestor Monitor: Narrowing in on Esperion Therapeutics, Inc. (NASDAQ:ESPR) - The Tribune (NASDAQ:ESPR)
lakecitytribune.com - January 27 at 11:43 PM
streetinsider.com logoEsperion Therapeutics (ESPR) Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of ... - StreetInsider.com (NASDAQ:ESPR)
www.streetinsider.com - January 26 at 6:25 PM
streetinsider.com logoEsperion Therapeutics (ESPR) Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid (NASDAQ:ESPR)
www.streetinsider.com - January 25 at 11:22 PM
finance.yahoo.com logoEsperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with Hypercholesterolemia (NASDAQ:ESPR)
finance.yahoo.com - January 25 at 6:22 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Wall Street Beacon (NASDAQ:ESPR)
wsbeacon.com - January 21 at 4:21 AM
News IconLooking Ahead for Esperion Therapeutics, Inc. (NASDAQ:ESPR); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:ESPR)
aikenadvocate.com - January 18 at 5:29 PM
News IconCheck on Average Directional Index for Esperion Therapeutics Inc. (ESPR) - Sherwood Daily (NASDAQ:ESPR)
sherwooddaily.com - January 18 at 5:29 PM
News IconWill The Needle Move For Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ESPR)
wsbeacon.com - January 17 at 5:42 AM
News IconStock ABR Esperion Therapeutics, Inc. (NASDAQ:ESPR) At 2.67 - Stock Observer (NASDAQ:ESPR)
www.thestockobserver.com - January 14 at 10:05 PM
News IconEsperion Therapeutics Inc ESPR Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ESPR)
www.bioportfolio.com - January 14 at 5:03 PM
News IconStock Reaching Most Volatile List Today: Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Wall Street Beacon (NASDAQ:ESPR)
wsbeacon.com - January 12 at 3:39 AM
News IconStock Getting Tripped Up In Session: Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Wall Street Beacon (NASDAQ:ESPR)
wsbeacon.com - January 12 at 3:39 AM
streetinsider.com logoEsperion Therapeutics (ESPR): Pivotal Bempedoic Acid Program ... - StreetInsider.com (NASDAQ:ESPR)
www.streetinsider.com - January 10 at 11:00 PM
smarteranalyst.com logoStock Update (NASDAQ:ESPR): Esperion Therapeutics Inc Announces Initiation of Global Cardiovascular Outcomes ... - Smarter Analyst (NASDAQ:ESPR)
www.smarteranalyst.com - January 10 at 11:00 PM
streetinsider.com logoEsperion Therapeutics (ESPR) Initiates CVOT Trial for Bempedoic Acid (NASDAQ:ESPR)
www.streetinsider.com - January 10 at 3:55 AM
streetinsider.com logoEsperion Therapeutics (ESPR) Initiates CVOT Trial for Bempedoic Acid - StreetInsider.com (NASDAQ:ESPR)
www.streetinsider.com - January 9 at 5:53 PM
finance.yahoo.com logoEsperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid (NASDAQ:ESPR)
finance.yahoo.com - January 9 at 5:53 PM
finance.yahoo.com logo8:24 am Esperion Therapeutics initiates the global cardiovascular outcomes trial to assess the effects of bempedoic acid on the occurrence of major cardiovascular events (NASDAQ:ESPR)
finance.yahoo.com - January 9 at 5:53 PM

Social

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Where is Esperion Therapeutics' stock going? Where will Esperion Therapeutics' stock price be in 2017?

12 brokers have issued 1 year price targets for Esperion Therapeutics' stock. Their predictions range from $12.00 to $67.00. On average, they expect Esperion Therapeutics' stock price to reach $26.54 in the next twelve months.

When will Esperion Therapeutics announce their earnings?

Esperion Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

Who owns Esperion Therapeutics stock?

Esperion Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Pentwater Capital Management LP (8.11%), Discovery Capital Management LLC CT (4.62%), FMR LLC (3.40%), Senzar Asset Management LLC (1.61%), State Street Corp (1.06%) and J. Goldman & Co LP (0.72%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben.

Who sold Esperion Therapeutics stock? Who is selling Esperion Therapeutics stock?

Esperion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FT Options LLC, Oxford Asset Management, Discovery Capital Management LLC CT, State Street Corp and Martingale Asset Management L P.

Who bought Esperion Therapeutics stock? Who is buying Esperion Therapeutics stock?

Esperion Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Pentwater Capital Management LP, J. Goldman & Co LP, Pinnacle Associates Ltd., Paulson & CO. Inc., Dimensional Fund Advisors LP, Elkfork Partners LLC and Keybank National Association OH. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben.

How do I buy Esperion Therapeutics stock?

Shares of Esperion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Esperion Therapeutics stock cost?

One share of Esperion Therapeutics stock can currently be purchased for approximately $24.37.

Esperion Therapeutics (NASDAQ:ESPR) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Earnings History Chart

Earnings by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Dividend History Chart

Dividend Payments by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Last Updated on 2/24/2017 by MarketBeat.com Staff